Fasinumab
From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by DMacks (talk | contribs) at 04:12, 22 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 04:12, 22 June 2020 by DMacks (talk | contribs) (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB))
Monoclonal antibody | |
---|---|
Type | ? |
Source | Human |
Target | HNGF |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6406H9896N1700O2026S46 |
Molar mass | 144618.27 g·mol−1 |
Fasinumab is a human monoclonal antibody designed for the treatment of acute sciatic pain.[1][2]
This drug was developed in collaboration by Teva Pharmaceutical Industries and Regeneron Pharmaceuticals.
It is currently at Phase III trials.
See also
References
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems | |||||||||
---|---|---|---|---|---|---|---|---|---|
Bone |
| ||||||||
Musculoskeletal |
| ||||||||
Circulatory |
| ||||||||
Neurologic |
| ||||||||
Angiogenesis inhibitor |
| ||||||||
Growth factor |
| ||||||||
|
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
Retrieved from "https://en.wikipedia.org/w/index.php?title=Fasinumab&oldid=963846419"